Sep 03, 2020
Viz.ai, the leading AI stroke platform, is the first AI software to receive a Medicare New Technology Add-on Payment, helping hospitals adopt advanced technology to improve stroke care
SAN FRANCISCO -Sept. 3, 2020- In a groundbreaking ruling, CMS has granted Viz.ai the first New Technology Add-on Payment (NTAP) for artificial intelligence software. NTAP, part of the CMS Inpatient Prospective Payment System (IPPS), was set up to support the adoption of cutting-edge technologies that have demonstrated substantial clinical improvement and ensure early availability to Medicare patients. In the US, stroke is the number one cause of long term disability, but is a treatable condition if identified early enough.
Viz.ai has been recognized by Forbes, Fast Company, and AuntMinnie as one of the leading AI healthcare companies in the US. The company provides software that improves clinical and financial outcomes1,2 by streamlining acute care, leading to shorter time to treatment, improved patient outcomes, reduced length of stay, and increased number of procedures.
“Since using Viz at our center, we have seen a decrease in time to treatment and an improvement in patient outcomes. This software should be considered now the gold standard for all systems treating stroke,” Dr. Adam Arthur, Professor of Neurosurgery University of Tennessee Health Sciences Center and Semmes-Murphey Clinic.
CMS has selected Viz.ai’s stroke software, Viz LVO, formally known as Viz ContaCT, as the first AI software to receive a Medicare New Technology Add-on Payment. Viz.ai demonstrated to CMS a significant reduction in time to treatment and improved clinical outcomes in patients suffering a stroke. Viz LVO has been granted a New Technology Add on Payment of up to $1,040 per use in patients with suspected strokes.
“Viz is the first software that meets CMS’s strict substantial clinical improvement criteria,” said Jayme Strauss, Executive Director of Neuroscience Piedmont Healthcare. “The extra reimbursement will empower hospitals as they strive to improve outcomes for stroke patients especially during a pandemic where hospitals have the additional cost burdens associated with COVID. The Viz.ai platform provides the clinical improvement needed to improve a stroke program significantly and, with NTAP, hospitals can offer it without significant financial burden.”
About Viz.ai, Inc.
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 220 million lives across 1,400+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies.
1. Hassan et al. (2020) 2. Morey et al. (2020)